Use of Hydroxychloroquine in Hair Disorders

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory properties.
• Autoimmune hair loss disorders, including lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and alopecia areata (AA), lack standardized treatment guidelines.
• HCQ's immunologic effects suggest potential utility in managing autoimmune-driven hair loss.

Purpose of the Study:

• To summarize existing literature on the efficacy of hydroxychloroquine (HCQ) for treating LPP, FFA, and AA.
• To evaluate the variable outcomes and treatment patterns associated with HCQ use in these conditions.

Main Methods:

• Literature review of studies investigating HCQ for LPP, FFA, and AA.
• Analysis of reported treatment regimens, including monotherapy and combination therapies.
• Assessment of treatment efficacy based on available study data.

Main Results:

• HCQ demonstrated variable efficacy across LPP, FFA, and AA, ranging from halting hair loss to no significant improvement.
• Successful patient outcomes were observed, but no standardized treatment protocols emerged.
• Treatment regimens varied, including HCQ monotherapy and combination with agents like steroids.

Conclusions:

• Hydroxychloroquine (HCQ) is a potential therapeutic option for clinicians treating LPP, FFA, and AA.
• Treatment decisions should involve individualized patient assessment, clinical judgment, and consideration of potential side effects.
• Further research may be needed to establish standardized treatment guidelines for HCQ in autoimmune hair loss.